Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials

Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.